In the wild, Lilly’s Mounjaro holds weight loss edge over Novo’s Ozempic Lily EvansDecember 1, 2023 Most of the huge groundswell for the two most common diabesity drugs — Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide — has been driven by Read More